Thursday, April 02, 2020 4:30:26 PM
Just curious ...
"... the impurity in some ranitidine products increases over time ..."
If an impurity is in a packaged (spelled sealed) product, how does the impurity increase over time? And how often is some? And though packaged, is it alive, and is that how it increases -- feeding on other ingredients?
Seems pretty vague. The FDA also made a request, not an order. That's because they don't have proof ... they only have undefined probabilities.
Then it continues: "... and when stored at higher than room temperatures ...".
OK, how much higher? Five degrees F? Five-hundred degrees F?
Onward: "... and may result in consumer exposure to unacceptable levels...".
May? Okay, give me some percentages. One percent? Five percent? Fifty percent? And what exactly is an acceptable level?
"NDMA is a probable human carcinogen ..."
I know exactly what that means. The cancer tests that humans have devised have all been proven (many years ago) to be faulty. Finally, humans have become honest enough to accept that; well, at least some of the time.
"... the impurity in some ranitidine products increases over time ..."
If an impurity is in a packaged (spelled sealed) product, how does the impurity increase over time? And how often is some? And though packaged, is it alive, and is that how it increases -- feeding on other ingredients?
Seems pretty vague. The FDA also made a request, not an order. That's because they don't have proof ... they only have undefined probabilities.
Then it continues: "... and when stored at higher than room temperatures ...".
OK, how much higher? Five degrees F? Five-hundred degrees F?
Onward: "... and may result in consumer exposure to unacceptable levels...".
May? Okay, give me some percentages. One percent? Five percent? Fifty percent? And what exactly is an acceptable level?
"NDMA is a probable human carcinogen ..."
I know exactly what that means. The cancer tests that humans have devised have all been proven (many years ago) to be faulty. Finally, humans have become honest enough to accept that; well, at least some of the time.
Recent TEVA News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/07/2026 08:03:44 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/07/2026 08:01:55 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/05/2026 08:00:07 PM
- Teva to Present at the BofA Securities Health Care Conference • GlobeNewswire Inc. • 05/04/2026 08:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/04/2026 08:02:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/04/2026 08:00:53 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/04/2026 12:12:51 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/30/2026 08:40:45 PM
- Teva’s 2025 Healthy Future Report Highlights Environmental and Access to Medicines Progress, Including Meeting All Sustainability-Linked Bond Targets • GlobeNewswire Inc. • 04/30/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/29/2026 08:06:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 11:00:20 AM
- Teva Delivers Strong Q1 2026 Results Driven by Innovative Portfolio Growth and Disciplined Execution • GlobeNewswire Inc. • 04/29/2026 11:00:00 AM
- Teva to Acquire Emalex Biosciences, Adding NDA-Ready, First-in-Class Therapy to Neuroscience Pipeline and Accelerating Teva’s Pivot to Growth Strategy • GlobeNewswire Inc. • 04/29/2026 10:30:00 AM
- Teva Launches Home Ground™ Schizophrenia Community, a New Online Resource Hub for People Living with Schizophrenia and Their Care Partners • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Community Routes: Access to Mental Health Care Provides Continued Funding for Mental Health Services at Free & Charitable Clinics • GlobeNewswire Inc. • 04/14/2026 12:00:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 03/31/2026 08:43:03 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/31/2026 08:41:07 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/31/2026 08:38:29 PM
- Teva Gains Biosimilar Momentum with U.S. FDA Approval of PONLIMSI™ (denosumab-adet) and Dual Filing Acceptance for Biosimilar Candidate to Xolair® (omalizumab) • GlobeNewswire Inc. • 03/30/2026 12:00:00 PM
- Teva to Host Conference Call to Discuss First Quarter 2026 Financial Results at 8 a.m. ET on April 29, 2026 • GlobeNewswire Inc. • 03/19/2026 08:30:00 PM
- Teva Releases Q1 2026 Aide Memoire • GlobeNewswire Inc. • 03/19/2026 08:30:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/04/2026 10:36:38 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/04/2026 10:28:47 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/04/2026 10:22:25 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/03/2026 10:46:00 PM
